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Abstract
Abdominal pain and bowel habits alterations are common 
symptoms in the general population. The investigation 
to differentiate organic from functional bowel disorders 
represents a considerable burden both for patients 
and public health service. The selection of patients 
who should undergo endoscopic and/or radiological 
procedures is one of the key points of the diagnostic 
process, which should avoid the abuse of invasive 
and expensive tests as well as the underestimation of 
potentially harmful diseases. Over the coming years, 
clinicians and researchers will be challenged to develop 
strategies to increase the patient’s compliance and to 
reduce the economic and social costs of the intestinal 
diseases.
© 2007 The WJG Press. All rights reserved.
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INTRODUCTION
For the sake of  simplicity, bowel diseases have been divided 
into organic (OBD) and functional (FBD) disorders. In the 
past, FBD was merely considered an “umbrella” for many 
clinical pictures where the term functional reflected an 
unknown etiology and/or pathogenesis and their existence 
was even denied by some physicians[1,2]. In the last years, 
the fast-growing insight into the pathogenesis of  intestinal 
diseases has been narrowing the field of  disturbances “not 
explained by structural or biochemical abnormalities”, 
in parallel with the progress of  diagnostic tools and the 
development of  novel technologies. Recent evidences, 
such as the role of  serotonin in visceral functions[3-5], the 
post-infective onset of  irritable bowel syndrome (IBS)[6] 
or data about potential neuroendocrine dysfunctions[7] 
shed light on the phenomena underlying FBD. The 
“biopsychosocial model” focused on the complex 
interplay among genetics, environment, psychosocial and 
physiological factors, significantly contributed to clarify the 
true genesis of  “functional” symptoms and to modify both 
treatment and clinical outcome[8]. However, while the new 
scenario of  pathogenesis suggests an overlapping between 
morphologic and functional abnormalities, in clinical 
practice the distinction is maintained in prognostic terms, 
as “functional” identifies scarcely evolutive and virtually 
harmless conditions.
As the intestine reacts to different stimuli with a limited 
array of  symptoms, the investigation to differentiate OBD 
and FBD represents a considerable burden for both the 
patients and public health service. 
The selection of  patients who should undergo 
endoscopic and/or radiological procedures is one of  the 
key points of  the diagnostic process, which should avoid 
the abuse of  invasive and expensive tests as well as the 
underestimation of  potentially dangerous diseases. In 
particular, we should take into account the high prevalence 
and increasing incidence of  colo-rectal cancer which, at 
an early stage, can be successfully treated by endoscopic 
resection. Nevertheless, colonoscopy is not advisable in 
all patients with abdominal complaints in the absence of  
“red flag” features (age > 45 years, anaemia, bleeding, 
fever, weight loss, etc.) (Figure 1). Chronic or recurrent 
abdominal pain and bowel habit alterations are common 
symptoms in the general population. Because a wide range 
of  etiologies may underlie these symptoms, they do not 
allow a differential diagnosis between OBD (neoplasm, 
infectious enteritis, Crohn’s disease, celiac disease, etc.) 
and FBD. Moreover, patients may present overlapping 
syndromes as OBD and FBD , are not mutually exclusive 
and can be present in the same patient. FBD, mainly 
IBS, which affect 5%-20% of  general population, are the 
most common intestinal disorders in both primary and 
secondary care[9-11]. Most patients are diagnosed and treated 
by general practitioners (GPs) and only those unresponsive 
to conventional treatment[10,12] are eventually referred to a 
gastroenterologist[9,13].
In order to improve the positive identification of  
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patients affected with FBD, the Rome classification system 
has been developed. Although these guidelines have 
raised controversies about duration, frequency, severity 
and terminology itself  of  symptoms, they have created 
a common language for FBD and are now considered 
the gold standard. Unfortunately, Rome criteria have 
been developed by and for specialists working in the 
secondary care setting;  they are ignored by many GPs 
and considered by others, as well as by many specialists, 
too complex and time-consuming and/or restrictive, 
suitable only for the tertiary care setting and for research 
purposes[14]. Therefore, many GPs and gastroenterologists 
are confident of  making a correct diagnosis based on their 
personal criteria[14,15] and, in the absence of  any biological 
or instrumental marker, FBD is still an exclusive diagnosis 
which often require extensive investigation. The recent 
Rome Ⅲ criteria appear to be simpler and less restrictive 
and hopefully will help the diagnosis of  FBD on clinical 
basis[16].
When FBD is suspected, the clinical criteria can be 
combined with a number of  non-invasive diagnostic tools. 
Unfortunately serological biomarkers of  inflammation 
such as erythrocyte sedimentation rate, C-reactive protein, 
white cell count, platelet count, are not sufficiently sensitive 
or sufficiently specific because they do not directly reflect 
the level of  local inflammation[17-19]. The faecal occult 
blood test is of  little use in detecting inflammatory bowel 
diseases (IBD) and has a low sensitivity for the diagnosis 
of  colon cancer, especially at an early stage[20,21]. Therefore, 
in recent years considerable effort has been devoted to 
find alternative solutions. The latest knowledge about 
the pathogenesis of  FBD (infection, food allergy or 
intolerance)[22-24], have focused attention on the role of  
microscopic inflammation, bacterial overgrowth, altered 
immunity and even more subtle alterations, whose effects 
are detectable in non-invasive manner, by analysing stools, 
breath samples and blood.
FAECAL MARKERS
Neutrophil-derived proteins
Faecal neutrophil-derived proteins (mainly calprotectin and 
lactoferrin) assessment is receiving increasing attention as 
promising tools to differentiate OBD and FBD; although 
their clinical use needs definitive confirmation especially in 
the work-up of  FBD, they could be the putative ideal test 
for non-invasive assessment of  intestinal inflammation[25-27]. 
Calprotectin is a 36-kDa calcium and zinc binding 
protein that accounts for about 60% of  total proteins in 
the cytosol fraction of  neutrophil granulocytes[28,29]. An 
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Figure 1  Suggested approach to the diagnosis of chronic abdominal symptoms.
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increase in faecal calprotectin levels in IBD, colorectal 
cancer and non-steroidal anti-inf lammatory drugs 
enteropathy has been reported[30-33]. In a study of  Dolwani, 
faecal calprotectin was superior to small bowel barium 
follow-up in identifying patients with organic diseases[34]. 
In Crohn’s disease (CD) and ulcerative colitis (UC), its 
levels closely correlated with the faecal excretion of  111In-
labelled leukocytes, which is considered to be the gold 
standard for measuring intestinal inflammation[35] and 
recently it has been reported that a high faecal calprotectin 
concentration may identify those IBD patients in remission 
who are at risk of  early relapse[36,37]. Calprotectin has a 
high negative predictive value for intestinal inflammation. 
It has low specificity for intestinal pathology but, at a cut-
off  of  30 mg/L (150 μg/g of  faeces by the new method), 
it showed a sensitivity of  100% in discriminating between 
active Crohn’s disease and IBS[27]. The combined use of  
presence/absence of  alarm features, Rome criteria and 
calprotectin test proved to be a non-invasive, effective 
mean of  screening patients for organic intestinal disease[38].
Lactoferrin is an iron-binding protein contained in 
organic fluid, intestinal mucus and in neutrophils. Similarly 
to calprotectin, faecal lactoferrin proved to be a simple, 
sensitive marker of  intestinal inflammation[25,39,40].
DNA 
The molecular genetics of  colorectal cancer provided the 
basis for the analysis of  faecal DNA[41]. Colonoscopy is 
the best tool for the diagnosis of  colorectal cancer but 
it cannot be proposed for a systematic screening of  the 
entire population > 50 years of  age. The recent availability 
of  faecal-based, multi-target DNA panel has allowed 
a better sensitivity than faecal occult blood test for the 
detection of  colorectal cancer[21]. This panel consists of  
different mutations (K-ras gene, APC gene, p53 gene), 
markers of  microsatellite-instability and markers of  
disordered apoptosis, clearly involved in the progression 
of  colorectal cancer. Although the performance of  faecal 
DNA testing is not comparable to colonoscopy, it is simple 
and non-invasive, therefore its use at frequent intervals 
might compensate for the lower diagnostic accuracy[21].
Pancreatic elastase
Chronic pancreatitis is a frequent cause of  abdominal 
pain and diarrhoea whose diagnosis often requires 
complex and expensive procedures. The assessment 
of  pancreatic elastase on stools seems to offer a better 
performance than previous non-invasive tests (i.e. serology, 
Pancreolauryl test, faecal tests for pancreatic enzyme) 
with a high sensitivity for moderate and severe pancreatic 
insufficiency[42,43]; this faecal test, like faecal neutrophil-
derived protein assessment, is easy to perform, requires 
a single stool sample and offers a great advantage in 
terms of  patient’s compliance. Although most authors 
reported poor sensitivity for mild disease, its use has been 
recommended as a first choice test in patients with chronic 
diarrhoea of  putative pancreatic origin[44].
If  these experimental data are confirmed in large 
controlled studies, the routine use of  faecal tests might 
contribute to the selection of  patients with abdominal 
complaints both in the first diagnosis and in the follow-up 
avoiding invasive and expensive procedures.
BREATH TESTS
Breath analysis is a simple and safe alternative to 
invasive tests to investigate digestive functions. Exhaled 
hydrogen (H2) and carbon (C) can be employed to assess 
malabsorption, gastrointestinal motility and H pylori 
infection. H2 in humans is produced only by bacterial 
fermentation of  carbohydrates[45]. This process has been 
related to the onset of  symptoms such as diarrhoea, 
bloating and abdominal pain[46,47]. Different hydrogen 
breath tests are currently used to detect carbohydrate 
malabsorption. Lactose, fructose, sorbitol are the most 
commonly tested carbohydrates, although their role in 
symptoms of  FBD is controversial, and the prevalence 
of  lactose, fructose and sorbitol  malabsorption in IBS 
patients is not different from healthy subjects[48].
Small intestinal bacterial overgrowth (SIBO) is a 
malabsorption syndrome characterized by more than 105 
colonic type bacterial/mL of  jejunal juice described in 
case of  structural bowel alterations (surgical blind loop, 
stenosis, etc), motility disturbances (pseudo-obstruction, 
diabetic autonomic neuropathy, sclerodermia) and also 
present in chronic diseases (liver cirrhosis, chronic 
pancreatitis, chronic renal failure)[49]. Recent data also 
indicate that an altered gut flora may play a pathogenic 
role both in IBS and IBD[50,51]. It has been shown that 
eradication of  SIBO eliminates IBS symptoms in 48% 
of  patients[52]. Although jejunal culture is considered the 
gold standard for the diagnosis of  SIBO, some drawbacks 
limit its widespread use; thus, glucose and lactulose breath 
tests are commonly employed. Breath tests based on 
the excretion of  CO2 subsequently measured by a mass 
spectrometer have been developed; they employ a variety 
of  13C substrates to investigate the exocrine pancreatic 
function (13C triolein, 13C mixed chain triglyceride)[53], 
gastric emptying (13C octanoate)[54], as well as in the 
diagnosis of  H pylori infection (13C urea)[55].
The s impl ic i ty and the safety of  breath tes ts 
encouraged a widespread use, but the data on their low 
diagnostic accuracy should be taken into account and their 
use on regular basis cannot be recommended in clinical 
practice[56].
SERUM
Recent literature highlighted that approximately 4% 
of  patients diagnosed as IBS are affected with celiac 
disease[57]. Altered bowel habits and abdominal pain, the 
clinical hallmark of  IBS, are common in celiac patients, 
and serological assessment for anti-endomysial and anti-
transglutaminase antibodies should be performed as a first 
level test when IBS is suspected. Many patients suffering 
from abdominal pain and/or bowel habit changes perceive 
their symptoms as related to some form of  dietary 
intolerance and show a good response to an exclusive 
diet. Nevertheless, any attempt to correlate food-specific 
IgE production and chronic abdominal symptoms has 
been disappointing[24,58]. Although it has been reported 
Costa F et al . Organic and functional intestinal disorders                                                                                     221
www.wjgnet.com
that sometimes IgE-mediated reactivity can present with 
chronic abdominal complaints, the measurement of  
food-specific IgE antibody concentrations to ascertain 
food intolerance in FBD is not justified and should be 
discouraged[59]. Preliminary data showed that high titres of  
food-specific IgG4 antibodies are present in IBS patients 
suggesting a diagnostic role in those cases of  IBS who 
could benefit mostly by an exclusive diet[60]. Their clinical 
follow-up and further research are needed to clarify the 
importance of  these findings and their role in clinical 
practice.
CONCLUSION
Likely the near future will lead to a deep revision of  the 
concept of  “functional disorder”. The striking progress 
in our knowledge of  the molecular basis of  diseases is 
identifying new models for FBD pathogenesis, which tend 
to be less “functional” and more “organic”.
These new evidences will have a relevant effect on the 
clinical management of  intestinal diseases. We are not far 
from the time when the development of  minimally or non-
invasive techniques will allow an accurate diagnosis, a serial 
monitoring and a “real time” adjustment of  therapy.
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